Obstacles to getting more people with TB treated extend beyond cost. It starts with locating people at greatest risk and expanding preventive treatment programmes.
Chest x-ray of a person with TB infection in both the right and left lungs.
Schira/Shutterstock.com
Bioinformatics can be applied to a range of problems, such as understanding the genome sequence of organisms or coming up with new drugs.
Two girls in white (1904) is a composite study of three of Ramsay’s sisters, who cared for him before his death from tuberculosis.
Art Gallery of New South Wales
Hugh Ramsay’s Two girls in white, was painted just two years before he died at the age of 28 in 1906. It is the central work in the National Gallery of Australia’s survey exhibition.
There is growing awareness of the negative impact of ‘parachute research’.
Shutterstock
Many of the most fundamental aspects of TB disease remain unknown. For example, after exposure to the organism that causes TB, why do only some people get infected and only some of those fall ill?
Ageing increases the risk of non-communicable diseases.
Shutterstock
Rapid population ageing has prompted researchers to study disease trends in older South Africans. The aim is to understand the role that specific health conditions play in ageing among rural people.
Millions of young children get malaria. These two got it in 2010.
AP Photo/Schalk van Zuydam
There’s a big market for new treatments for TB, malaria and other ailments. But most of these diseases afflict low-income people unable to pay for medicine.
A prototype of the pills-on-a-coil prototype that delivers medicine while it sits in the gut.
Malvika Verma and Karan Vishwanath
Malvika Verma, Massachusetts Institute of Technology (MIT)
Treating infectious diseases is a huge challenge because patients often fail to take the medicine for the long duration, especially for tuberculosis. Now there’s a new device that may help.
Tuberculosis kills more people globally than any other infectious disease. A human-rights approach and investment in quality care are essential to ending the global epidemic.
New research holds promise of a shorter treatment course for people with drugresistant- TB.
Daniel Irungu/EPA
Infectious Diseases Physician and Senior Clinical Lecturer, Liverpool School of Tropical Medicine and Honorary Research Associate, University of Liverpool
Head of the Immunology Research Group at the Division of Molecular Biology & Human Genetics, Department of Biomedical Sciences, Faculty of Medicine & Health Sciences, Stellenbosch University